Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany.
Curr Opin Lipidol. 2012 Dec;23(6):569-75. doi: 10.1097/MOL.0b013e328359b19f.
Over the last few years, a variety of new antidiabetic drugs have been approved for clinical use and novel agents are currently under development. All of these are facing new regulations created by the demand to not only lower HbA1c but also provide long-term clinical benefit and cardiovascular safety.
The present review will discuss the following novel therapeutic options: GLP-1 mimetics and DPP-4 inhibitors are new antidiabetic drugs which favourably affect glucose metabolism without a significant risk for hypoglycaemic events and preliminary clinical data suggesting potential beneficial effects with respect to cardiovascular risk reduction. In addition, new antidiabetic concepts include SGLT2 inhibition, dual peroxisome proliferator-activated receptor agonists and G-protein receptor agonists, all of which provide beneficial cardiometabolic characteristics.
The development of novel antidiabetic strategies currently does not only focus on potent glucose-lowering properties but also on safety aspects and potential cardiovascular benefits.
在过去的几年中，多种新型抗糖尿病药物已获准临床应用，目前正在开发新的药物。所有这些都面临着新的规定，不仅要降低 HbA1c，还要提供长期的临床获益和心血管安全性。
本综述将讨论以下新型治疗选择：GLP-1 类似物和 DPP-4 抑制剂是新型抗糖尿病药物，它们对葡萄糖代谢有有利影响，而低血糖事件的风险不大，初步临床数据表明它们可能对降低心血管风险有有益的影响。此外，新型抗糖尿病药物的概念还包括 SGLT2 抑制、双重过氧化物酶体增殖物激活受体激动剂和 G 蛋白受体激动剂，它们都具有有益的心脏代谢特征。
新型抗糖尿病策略的发展目前不仅关注强效的降血糖特性，还关注安全性方面和潜在的心血管益处。
